EMA starts evaluation of Moderna's booster application
Moderna has applied for the European health authority's approval for the use of its Covid-19 vaccine, Spikevax, as a booster dose in re-vaccination schemes.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
The European Medicines Agency (EMA) has begun its assessment of data from US-based Moderna, which has applied for the approval of its Spikevax in use as a Covid-19 booster vaccine, the EMA reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA begins assessment of Pfizer booster application
For subscribers
Sanofi pivots toward boosters after Covid vaccine delays
For subscribers
.jpg&w=384&q=75)
